Lexaria Bioscience Corp (LEXX)
2.35
+0.16
(+7.31%)
USD |
NASDAQ |
Apr 26, 16:00
2.35
0.00 (0.00%)
After-Hours: 20:00
Lexaria Bioscience Enterprise Value: 25.12M for April 26, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 26, 2024 | 25.12M |
| April 25, 2024 | 23.05M |
| April 24, 2024 | 23.18M |
| April 23, 2024 | 23.70M |
| April 22, 2024 | 24.02M |
| April 19, 2024 | 23.18M |
| April 18, 2024 | 23.83M |
| April 17, 2024 | 24.99M |
| April 16, 2024 | 24.60M |
| April 15, 2024 | 20.48M |
| April 12, 2024 | 22.15M |
| April 11, 2024 | 27.18M |
| April 10, 2024 | 29.11M |
| April 09, 2024 | 29.63M |
| April 08, 2024 | 32.34M |
| April 05, 2024 | 33.48M |
| April 04, 2024 | 35.25M |
| April 03, 2024 | 38.04M |
| April 02, 2024 | 38.80M |
| April 01, 2024 | 38.17M |
| March 28, 2024 | 40.83M |
| March 27, 2024 | 41.84M |
| March 26, 2024 | 42.86M |
| March 25, 2024 | 44.88M |
| March 22, 2024 | 38.80M |
| Date | Value |
|---|---|
| March 21, 2024 | 38.42M |
| March 20, 2024 | 41.72M |
| March 19, 2024 | 45.52M |
| March 18, 2024 | 37.92M |
| March 15, 2024 | 44.25M |
| March 14, 2024 | 43.62M |
| March 13, 2024 | 50.59M |
| March 12, 2024 | 47.80M |
| March 11, 2024 | 72.26M |
| March 08, 2024 | 62.97M |
| March 07, 2024 | 56.77M |
| March 06, 2024 | 50.33M |
| March 05, 2024 | 36.70M |
| March 04, 2024 | 32.00M |
| March 01, 2024 | 31.01M |
| February 29, 2024 | 37.57M |
| February 28, 2024 | 29.17M |
| February 27, 2024 | 27.31M |
| February 26, 2024 | 25.58M |
| February 23, 2024 | 24.58M |
| February 22, 2024 | 25.32M |
| February 21, 2024 | 25.07M |
| February 20, 2024 | 25.93M |
| February 16, 2024 | 23.73M |
| February 15, 2024 | 23.00M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
0.7568M
Minimum
May 10 2023
81.70M
Maximum
Apr 29 2019
22.27M
Average
19.66M
Median
Jan 11 2021
Enterprise Value Benchmarks
| Aurinia Pharmaceuticals Inc | 359.58M |
| Sunshine Biopharma Inc | -15.35M |
| Acasti Pharma Inc | 2.144M |
| Edesa Biotech Inc | 9.751M |
| Xenon Pharmaceuticals Inc | 2.417B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.6495M |
| Revenue (Quarterly) | 0.145M |
| Total Expenses (Quarterly) | 0.813M |
| EPS Diluted (Quarterly) | -0.06 |
| Profit Margin (Quarterly) | -448.0% |
| Earnings Yield | -28.94% |
| Normalized Earnings Yield | -28.75 |